Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Mayne Pharma Group ( (AU:MYX) ) has shared an announcement.
Mayne Pharma has secured a court order requiring Cosette Pharmaceuticals to pay $13.27 million in legal costs, plus interest, following Mayne’s successful defence last year of proceedings over the attempted termination of a Scheme Implementation Deed. The New South Wales Supreme Court had previously dismissed all of Cosette’s claims and issued an adverse costs order, and is now expected to finalise ancillary orders on interest, payment timing and additional cost applications, bolstering Mayne Pharma’s financial position after the protracted dispute.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma Group is an ASX-listed specialty pharmaceutical company that commercialises novel medicines aimed at making treatments safer and more accessible. The company has a strong presence in U.S. dermatology and women’s health markets, and also provides contract development and manufacturing services globally, underpinned by a 40-year history in oral drug delivery innovation.
Average Trading Volume: 439,969
Technical Sentiment Signal: Sell
Current Market Cap: A$186.1M
See more insights into MYX stock on TipRanks’ Stock Analysis page.